阿尔茨海默病的细胞阶段
Bart De Strooper1, Eric Karran2
1VIB Center for the Biology of Disease, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire Ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium; Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK.
Cell
|February 13, 2016
概括
阿尔茨海默病 (AD) 的粉样蛋白假设可能过于简单. 一个复杂的细胞阶段涉及星球细胞,微质细胞和血管系统对于理解神经退化进展至关重要.
科学领域:
- 神经科学
- 细胞生物学
- 阿尔茨海默病的研究
背景情况:
- 对于阿尔茨海默病 (AD) 的传统粉样蛋白假设提出了从粉样蛋白-β (Aβ) 到痴呆症的线性级联.
- 这种以神经元为中心的模型与阿尔茨海默病进展的临床观察相冲突.
- 这可能涉及到更复杂的多细胞相互作用.
研究的目的:
- 审查阿尔茨海默病发病过程中复杂细胞阶段的证据.
- 挑战简单的线性粉样蛋白级联模型.
- 倡导整体方法,包括质细胞和血管系统.
主要方法:
- 对阿尔茨海默病现有研究的文献综述.
- 对细胞反和涉及天体细胞,微质细胞和血管的传递机制的分析.
- 讨论当前模型的局限性.
主要成果:
- 证据支持在阿尔茨海默氏症中出现不可逆转的神经退化之前的长期复杂细胞阶段.
- 星球细胞,微质细胞和血管系统表现出复杂的反和前反应.
- 粉体假设提出的直接因果关系是不够的.
结论:
- 一个整体的,多细胞的视角对于理解阿尔茨海默病至关重要.
- 需要单细胞技术的进步来确定疾病进展的关键时刻.
- 未来的研究应该集中在AD细胞和系统的复杂相互作用上.
相关概念视频
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Amyloid Fibrils
12.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.9K
Amyloid Fibrils
6.9K
6.9K
Aging
975
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
975
Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K


